

The Crystal Structure of Pirprofen (C₁₃H₁₄ClNO₂), A Non-Steroidal Antiinflammatory Agent

Yang Bae Kim and Il Yeong Park¹

College of Pharmacy, Seoul National University, Seoul 151-742 and ¹College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea

(Received December 11, 1995)

The molecular structure of pirprofen, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)- α -methylbenzeneacetic acid, was determined by single crystal X-ray diffraction analysis. The compound was recrystallized from a mixture of chloroform and toluene in triclinic, space group *P* $\bar{1}$, with *a*=4.577(1), *b*=11.213(2), *c*=12.485(2) Å, α =107.39(1), β =97.79(1), γ =92.03(2), and *Z*=2. The calculated density is 1.384 g/cm³. The structure was solved by the direct method and refined by full matrix least-squares procedure to the final R value of 0.034 for 1681 independent reflections. The non-aromatic dihydropyrrol group is found to be coplanar to the central aromatic ring. The molecules are dimerized through the intermolecular hydrogen bonds at the carboxyl group in the crystal.

Key Words : Pirprofen, Antiinflammatory agent, Crystal structure, X-ray diffraction, Hydrogen bond

INTRODUCTION

Pirprofen (Fig. 1) is a non-steroidal antiinflammatory drug (NSAID), related structurally to drugs such as ibuprofen, ketoprofen, and naproxen (Korolkovas, 1988). The compound is widely used in rheumatoid arthritis, osteoarthritis, etc. However gastrointestinal complaints are the side effects reported most frequently as in cases of other NSAIDs (Todd and Beresford, 1986).

It is known that the NSAIDs inhibit prostaglandin biosynthesis, or more specifically the enzyme cyclooxygenase (Bray and Gordon, 1978; Tomlinson *et al.*, 1972). As an attempt to understand the mode of interaction of the drug molecules to the target enzyme, we have determined the 3D structures of some NSAIDs during the days (Kim *et al.*, 1986; 1987;

1988; 1989; 1990; 1993a; 1993b). And in this paper, we are reporting the structure of pirprofen to provide precise and useful informations necessary for the understanding and designing of a more useful NSAID.

MATERIALS AND METHODS

The compound was kindly supplied from Searle Ciba-Geigy Korea Ltd. Colorless prismatic crystals were grown by the slow evaporation from a mixture of chloroform and toluene at room temperature. A crystal of suitable size was mounted on an Enraf-Nonius CAD4 diffractometer. After obtaining cell parameters, intensity data within range of $\theta \leq 60^\circ$ were collected precisely. The significant descriptors explaining the experimental procedure in detail are summarized in Table I.

The structure was solved by the direct method with *MULTAN84* (Main *et al.*, 1984) and refined by full matrix least squares procedure to the final R value of 0.034 (unit weight) with *SHELX76* (Sheldrick, 1976) and *MoLEN* (Fair, 1990). The calculations were performed on a microVAX 3100 and a personal computer. The atomic scattering factors were taken from "International Tables for X-ray Crystallography" (The International Union of Crystallography, 1974).




Fig. 1. Pirprofen.

Correspondence to: Yang Bae Kim, College of Pharmacy, Seoul National University, Seoul 151-742, Korea

RESULTS AND DISCUSSION


The final atomic coordinates and equivalent iso-

Table I. Descriptors for the experimental procedure


CRYSTAL DATA	
$C_{13}H_{14}ClNO_2$	CuK α radiation
$M_r=251.71$	$\lambda=1.5418 \text{ \AA}$
Triclinic	Cell parameters from 25 reflections
$P\bar{1}$	$\theta=12.7\text{--}31.4^\circ$
$a=4.577(1) \text{ \AA}$	$\mu=2.592 \text{ mm}^{-1}$
$b=11.213(2) \text{ \AA}$	$T=293^\circ\text{K}$
$c=12.485(2) \text{ \AA}$	Prism
$\alpha=107.39(1)^\circ$	$0.22 \times 0.25 \times 0.27 \text{ mm}$
$\beta=97.79(1)^\circ$	Colorless
$\gamma=92.03(2)^\circ$	
$V=603.9(2) \text{ \AA}^3$	
$Z=2$	
$D_x=1.384 \text{ g/cm}^3$	
$D_m=1.38 \text{ g/cm}^3$ by flotation in KI solution	
DATA COLLECTION	
Enraf-Nonius CAD-4 diffractometer	$R_{int}=0.021$
$\omega/2\theta$ scans	$\theta_{max}=60.0^\circ$
Absorption correction: none	$h=-5 \rightarrow 5$
1924 measured reflections	$k=-12 \rightarrow 12$
1759 independent reflections	$l=0 \rightarrow 14$
1681 observed reflections	3 standard reflections
$[F > 3\sigma(F)]$	frequency: 60 min
	intensity decay: 1.7 %
REFINEMENT	
Refinement on F	Unit weights applied
$R=0.035$	$(\Delta/\sigma)_{max}=0.005$
$wR=0.034$	$\Delta\rho_{max}=0.256 \text{ e/\AA}^3$
$S=0.394$	$\Delta\rho_{min}=-0.207 \text{ e/\AA}^3$
1681 reflections	Extinction correction: none
210 parameters	Atomic scattering factors from <i>International Tables for X-ray Crystallography</i>
All H-atom parameters refined	

Table II. Fractional atomic coordinates and equivalent isotropic displacement parameters (\AA^2).
$$U_{eq} = (1/3) \sum_i \sum_j U_{ij} a_i^* a_j^* \cdot a_i \cdot a_j$$

Atom	x	y	z	U_{eq}
CL	.5640(2)	.2357(1)	.4814(0)	.076(0)
O(1)	.1166(4)	.5189(2)	.1429(2)	.070(1)
O(2)	-.2548(4)	.3989(2)	.0238(1)	.069(1)
N(1)	.5585(5)	.0004(2)	.2584(2)	.056(1)
C(1)	.0194(5)	.2926(2)	.2297(2)	.042(1)
C(2)	.1891(5)	.3011(2)	.3327(2)	.044(1)
C(3)	.3698(5)	.2064(2)	.3442(2)	.044(1)
C(4)	.3932(5)	.0999(2)	.2550(2)	.044(1)
C(5)	.2199(6)	.0956(2)	.1506(2)	.050(1)
C(6)	.0423(5)	.1888(2)	.1396(2)	.048(1)
C(7)	.7553(7)	-.0148(3)	.3557(2)	.063(1)
C(8)	.8615(7)	-.1401(3)	.3039(3)	.086(1)
C(9)	.7513(7)	-.1918(3)	.1976(3)	.076(1)
C(10)	.5460(7)	-.1079(2)	.1561(2)	.065(1)
C(11)	-.1889(5)	.3936(2)	.2150(2)	.046(1)
C(12)	-.1026(5)	.4417(2)	.1213(2)	.047(1)
C(13)	-.1909(7)	.5029(2)	.3227(2)	.060(1)

**Fig. 2.** Stereoscopic view of the molecule drawn by ORTEP (Johnson, 1976) with the atomic numbering scheme. The displacement ellipsoids are drawn at the 50% probability level. H atoms are drawn as small circles of arbitrary radii.**Table III.** Selected geometric parameters (\AA , $^\circ$).

C(3)--CL	1.750(2)	C(3)--C(4)	1.387(3)
C(4)--N(1)	1.377(3)	C(7)--C(8)	1.490(4)
C(7)--N(1)	1.469(3)	C(9)--C(8)	1.300(4)
C(10)--N(1)	1.468(3)	N(1)--C(10)	1.468(3)
H(O1)--O(1)	0.85(3)	C(9)--C(10)	1.503(3)
C(7)-N(1)-C(4)	127.9(2)	C(4)-C(3)-CL	123.5(2)
C(10)-N(1)-C(4)	119.9(2)	C(9)-C(8)-C(7)	114.0(2)
C(10)-N(1)-C(7)	112.2(2)	C(9)-C(10)-N(1)	102.1(2)

**Fig. 3.** Side view of the molecule (viewing down from C(7) to C(10)).

tropic temperature factors are listed in Table II. The list of structure factors, anisotropic displacement parameters, hydrogen atomic coordinates and complete geometry are available upon request.

The stereoscopic view of the molecule drawn by ORTEP (Johnson, 1976) together with the atomic numbering scheme is shown in Fig. 2. All of the molecular dimensions are in the reasonable range, and some selected geometric parameters are collected in Table III. The dihydropyrrol group, that is non-aromatic, is quite planar itself ($\sum(\Delta_i)^2 = 2.9 \times 10^{-5} \text{ \AA}^2$), and which in turn, is nearly coplanar to chlorophenyl ring with the dihedral angle of 2.7° . Fig. 3 shows the planar shape of the molecule clearly. The atoms around the nitrogen also have planar arrangement ($\sum(\Delta_i)^2 = 2.4 \times 10^{-5} \text{ \AA}^2$) rather than py-




Fig. 4. Crystal packing for pirprofen. The broken lines indicate OH...O type hydrogen bonds.

ramidal, which indicates having more sp^2 character than sp^3 on the nitrogen atom.

The molecular packing is presented in Fig. 4. In the crystal, the molecules are dimerized through the intermolecular hydrogen bonds between the carboxyl groups each other. The distance between O(1) and O(2) at (-x, 1-y, -z) is 2.654(3) Å (H(O1)...O'(2): 1.86(4) Å), and the interatomic angle of $\angle O(1)-H(O1)\cdots O'(2)$ is 156(3)°. The other interatomic distances are in the range of normal *van der Waals'* contacts.

ACKNOWLEDGEMENTS

This work was supported by the research grant from Korea Research Foundation (1993).

REFERENCES CITED

- Bray, M. A. and Gordon, D., Prostaglandin production by macrophages and the effect of anti-inflammatory drugs, *Br. J. Pharmac.*, 63, 635-642 (1978).
- Fair, C. K., *MolEN: Structure Determination System*, Delft Instruments, The Netherlands, 1990.
- Johnson, C. K., *ORTEPII: A FORTRAN Thermal-Ellipsoid Plot Program for Crystal Structure Illustrations* (ORNL-5138), Oak Ridge National Laboratory, Tennessee, 1976.
- Kim, Y. B., Kim, S. J. and Koo, J. H., Refinement of the structure of alclofenac, 4-allyloxy-3-chloro-

phenylacetic acid (C₁₁H₁₁O₃Cl), *Arch. Pharm. Res.*, 9(4), 223-227 (1986).

- Kim, Y. B., Song, H. J. and Park, I. Y., Refinement of the structure of naproxen, (+)-6-methoxy- α -methyl-2-naphthaleneacetic acid, *Arch. Pharm. Res.*, 10(4), 232-238 (1987).
- Kim, Y. B., Park, I. Y. and Park, Y. H., The crystal structure of fenbufen, 3-(4-biphenylcarbonyl)propionic acid (C₁₆H₁₄O₃), a non-steroidal anti-inflammatory agent, *Arch. Pharm. Res.*, 11(2), 127-133 (1988).
- Kim, Y. B., Park, I. Y. and Park, Y. H., The crystal structure of cinmetacin (C₂₁H₁₉NO₄), a non-steroidal anti-inflammatory agent, *Arch. Pharm. Res.*, 12(1), 52-57 (1989).
- Kim, Y. B., Park, I. Y. and Lah, W. R., The crystal structure of naproxen sodium, (C₁₄H₁₃O₃Na), a non-steroidal anti-inflammatory agent, *Arch. Pharm. Res.*, 13(2), 166-173 (1990).
- Kim, Y. B., Kim, J. A. and Park, I. Y., The crystal structure of acemetacin monohydrate (C₂₁H₁₈NO₆Cl · H₂O), a non-steroidal anti-inflammatory agent. *Arch. Pharm. Res.*, 16(2), 134-139 (1993a).
- Kim, Y. B., Kwon, Y. H., Park, I. Y., Lee, B. J. and Kim, C.-K., The crystal structure of tenoxicam (C₁₃H₁₁N₃O₄S₂), a non-steroidal anti-inflammatory agent, *Seoul Univ. J. Pharm. Sci.*, 18, 1-12, (1993b).
- Korolkovas, A., Antiphilologistics, In Korolkovas, A. (Eds.), *Essentials of Medicinal Chemistry*, Wiley, New York, 1988, pp. 1091-1103.
- Main, P., Germain, G. and Woolfson, M. M., *MULTAN84: A System of Computer Program for the Automatic Solution of Crystal Structures from X-ray Diffraction Data*, Univ. of York, England, 1984.
- Sheldrick, G. M., *SHELX76: Program for Crystal Structure Determination*, Univ. of Cambridge, England, 1976.
- The International Union of Crystallography, *International Tables for X-ray Crystallography, Vol. III*, Kynoch Press, Birmingham, England, 1974.
- Todd, P. A. and Beresford, R., Pirprofen, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, *Drugs*, 32, 509-537 (1986).
- Tomlinson, R. V., Ringold, N. J., Qureshi, M. C. and Forchielli, E., Relationship between inhibition of prostaglandin synthesis and drug efficacy: Support for current theory on mode of action of aspirin-like drugs, *Biochem. Biophys. Res.*, 46(2), 552-559 (1972).